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Blood pressure lowering and major cardiovascular
events in people with and without chronic kidney
disease: meta-analysis of randomised controlled trials
OPEN ACCESS
Blood Pressure Lowering Treatment Trialists’ Collaboration
Abstract
Objective To define the cardiovascular effects of lowering blood pressure
in people with chronic kidney disease.
Design Collaborative prospective meta-analysis of randomised trials.
Data sources and eligibility Participating randomised trials of drugs
to lower blood pressure compared with placebo or each other or that
compare different blood pressure targets, with at least 1000 patient years
of follow-up per arm.
Main outcome measures Major cardiovascular events (stroke,
myocardial infarction, heart failure, or cardiovascular death) in composite
and individually and all cause death.
Participants 26 trials (152 290 participants), including 30 295 individuals
with reduced estimated glomerular filtration rate (eGFR), which was
defined as eGFR <60 mL/min/1.73m2.
Data extraction Individual participant data were available for 23 trials,
with summary data from another three. Meta-analysis according to
baseline kidney function was performed. Pooled hazard ratios per 5 mm
Hg lower blood pressure were estimated with a random effects model.
Results Compared with placebo, blood pressure lowering regimens
reduced the risk of major cardiovascular events by about a sixth per 5
mm Hg reduction in systolic blood pressure in individuals with (hazard
ratio 0.83, 95% confidence interval 0.76 to 0.90) and without reduced
eGFR (0.83, 0.79 to 0.88), with no evidence for any difference in effect
(P=1.00 for homogeneity). The results were similar irrespective of
whether blood pressure was reduced by regimens based on angiotensin
converting enzyme inhibitors, calcium antagonists, or diuretics/β blockers.
There was no evidence that the effects of different drug classes on major
cardiovascular events varied between patients with different eGFR (all
P>0.60 for homogeneity).
Conclusions Blood pressure lowering is an effective strategy for
preventing cardiovascular events among people with moderately reduced
eGFR. There is little evidence from these overviews to support the
preferential choice of particular drug classes for the prevention of
cardiovascular events in chronic kidney disease.
Introduction
Chronic kidney disease, most commonly defined by a reduced
glomerular filtration rate (GFR) or abnormal concentrations of
proteinuria, or both, is an important public health problem,
affecting 10-15% of the adult general population.1-3 It is
associated with an increased risk of kidney failure and
cardiovascular disease.4-6 Individuals with early chronic kidney
disease are more likely to experience a cardiovascular event
than kidney failure,7 and precise and reliable evidence about the
effects of strategies to prevent cardiovascular disease in this
large population of patients is of great importance.
Blood pressure is an important determinant of the risk of
cardiovascular disease in the general population.8 It is well
established that interventions that lower blood pressure prevent
cardiovascular events.9 10 Blood pressure is commonly raised
in individuals with chronic kidney disease,5 6 and guidelines
recommend lower blood pressure targets in this population than
in people without chronic kidney disease.11 12 Several studies
have also suggested particular benefits of drug classes acting
through the renin-angiotensin system for the prevention of renal
complications.13 The evidence that lowering blood pressure is
beneficial for patients with chronic kidney disease as well as
those without, however, remains limited, and the comparative
efficacy of different regimens to lower blood pressure on the
risk of cardiovascular events in patients with andwithout chronic
kidney disease remains uncertain.14-19
The Blood Pressure Lowering Treatment Trialists’
Collaboration20 was established to perform a series of
prospectively defined overviews of randomised trials to
investigate the effects of blood pressure lowering drugs on
cardiovascular morbidity and mortality, including assessments
of the comparative effects of regimens between major patient
subgroups. This analysis, prespecified in the original
collaboration protocol,20 quantifies the proportional benefits of
blood pressure lowering, and the comparative effects of different
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classes of blood pressure lowering drugs in individuals with
and without chronic kidney disease.
Methods
Data sources and study selection
Trials were eligible for inclusion in this prospective collaborative
meta-analysis if they met one of the following criteria: patients
were randomised to a blood pressure lowering drug/regimen or
a control group (placebo or less intensive blood pressure
lowering regimen) or patients were randomised between
regimens based on different classes of drugs to lower blood
pressure. Trials were also required to have a minimum of 1000
patient years of planned follow-up in each randomised arm and
not to have presented or published their main results before
finalisation of the overview protocol in July 1995.20 The
collaboration was jointly established by the principal
investigators in 1995, and the inclusion criteria for the
overviews20 specified that results of trials reported only after
this time could be included. In the early years of the
collaboration, participants contributed aggregate trial data but,
over time, agreed to provide individual patient data. New trials
were identified by a range of methods including computer aided
literature searches, scrutiny of abstracts and proceedings of
meeting, and by inquiring among colleagues, collaborators, and
the manufacturers of antihypertensive drugs. Determination of
eligibility was based on a review of details of the study design
and quality of the study, regardless of main results of each trial
(appendix table 1). The principal investigators for eligible trials
were invited to join the collaboration as they were identified.
Trials for which data by kidney function had been obtained by
April 2012 were included in these analyses. For this overview,
data were available from 26 trials providing either individual
participant data including serum creatinine concentrations (23
trials21-44) or summary data stratified by estimated glomerular
filtration rate (tabular data from two trials15 45 and published
hazard ratios from one trial14). Among them, 25 trials14 15 21-44
were included in the main analyses, while one trial45 contributed
participants only to the reduced eGFR stratum and was included
in sensitivity analyses. Data regarding urinary protein excretion
at baseline were available for 11 trials.21 22 24 27-32 37 40 Two
trials15 34 39 did not provide information regarding the combined
endpoint of major cardiovascular events according to chronic
kidney disease status but provided data for other endpoints. The
individual participant data requested included characteristics of
participants recorded at screening or randomisation, selected
measurements during follow-up, and details of all outcomes
during the scheduled follow-up period. We used the Cochrane
Collaboration’s tool to assess the risk of bias.46
Glomerular filtration rates and proteinuria
Glomerular filtration rates were estimated with the modification
of diet in renal disease formula7:
eGFR=186.3×(serum creatinine/88.4)−1.154×(age)−0.203×1.210 (if
black)×0.742 (if female)
where eGFR is in mL/min/1.73 m2, age is in years, and serum
creatinine is in µmol/L. The participants were divided into two
categories of baseline eGFR (≥60 mL/min/1.73 m2 or and <60
mL/min/1.73 m2) with established cutpoints recommended in
renal guidelines.11 Published data from two trials in which kidney
function was estimated with the Cockcroft-Gault formula14 or
125-iothalamate clearance45 and patients were categorised as
having eGFR <65 mL/min and ≥65 mL/min were deemed
sufficiently comparable and included in the main analysis. The
presence of proteinuria was defined as any of the following:
urinary albumin excretion rate s>200 μg/min or >300 mg/day,
urinary albumin concentration >200 mg/L, urinary albumin
creatinine ratio >300 μg/mg, or a urinary protein dipstick test
result of 1+ or greater.7 Stages of chronic kidney disease were
defined according to the guidelines from the Kidney Disease
Outcomes Quality Initiative (K/DOQI).11
Outcomes
The six outcomes were defined according to the international
classification of diseases and were prespecified in the
collaboration’s protocol.20 Outcomes were stroke (non-fatal
stroke or death from cerebrovascular disease), coronary heart
disease (non-fatal myocardial infarction or death from coronary
heart disease including sudden death), heart failure (causing
death or requiring admission to hospital), cardiovascular death,
and total mortality. Themain outcomewasmajor cardiovascular
events comprising stroke, coronary heart disease, heart failure,
and cardiovascular death. Only the first event of the relevant
outcome type was included in each analysis.
Treatment comparisons
The treatment comparisons tested were prespecified in the
original protocol.20 In the broad group of trials comparing an
active treatment and a control, we carried out separate overviews
for angiotensin converting enzyme (ACE) inhibitor based
regimens versus placebo; calcium antagonist based regimens
versus placebo; and more intensive versus less intensive blood
pressure lowering regimens. In the broad group of trials
comparing different active agents, we carried out separate
overviews for ACE inhibitor based regimens versus conventional
treatment (diuretics or β blocker based regimens); calcium
antagonist based regimens versus conventional treatment; and
ACE inhibitor based regimens versus calcium antagonist based
regimens.
Data synthesis and analysis
Blood pressure reductions
The reduction in blood pressure in each trial arm was calculated
as the mean of the difference between each participant’s mean
blood pressure during follow-up and their blood pressure at
baseline. The mean difference in blood pressure between
randomised groups was then calculated by subtracting the values
for the two arms according to chronic kidney disease status.
Meta-analyses of subgroups according to kidney
function.
To investigate the effects of active treatment compared with
placebo, more intensive compared with less intensive regimens,
or different drug classes on the outcomes in patients with
different baseline eGFR, we performedmeta-analyses according
to kidney function. All the meta-analyses used a two stage
approach whereby the risk estimates were first summarised in
each trial and then combined.
For each trial and each outcome, we estimated the risk estimates
separately for each subgroup, according to the intention to treat
principle.We computed hazard ratios or odds ratios using a Cox
proportional hazard regression model (20 trials providing time
to event data21 24-42 44) or a logistic regression model (three trials
in which time to event data were not available22 23 43) in the 23
trials for which individual patient data were available. Among
the three remaining trials for which data were obtained from
the investigators or published reports, we estimated the hazard
ratios and variances with a Cox model for one trial14 and
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calculated the relative risks and its variances from first principles
using tabular data for two trials.15 45 Although hazard ratios,
odds ratios, and relative risks are not the same, we have shown
the risk estimates as hazard ratios because these risk estimates
have similar values under the condition of low incidence rates
of outcomes and most risk estimates in this study were hazard
ratios. Additionally, we carried out sensitivity analyses to
examine the impact of removing the five trials15 22 23 43 45 in which
the hazard ratios were unavailable for the risk estimates from
all analyses. Pooled estimates of hazard ratios and 95%
confidence intervals were calculated separately for each
subgroup by a random effects model with the method of
DerSimonian and Laird. The “metan” routine in Stata was used
for pooled estimates. The heterogeneity in treatment effects
between trials included for each comparison was estimated with
Cochrane’s Q and I2. The consistency of treatment effects across
the subgroups of chronic kidney disease status was tested with
χ2 tests of homogeneity. The potential for publication bias across
included trials was evaluated with Begg’s test and Egger’s test
for funnel plot asymmetry with the “metabias” routine (with
P<0.10 taken as significant) and the impact of any asymmetry
evaluated with the trim and fill analysis47 with the “metatrim”
routine in Stata.
Blood pressure weighted meta-analyses of
subgroups according to kidney function.
For the meta-analysis weighted blood pressure reduction in the
placebo controlled trials, we calculated pooled estimates per 5
mm Hg reduction in systolic blood pressure over time as
exp[5*(∑∆SBPi*Wi*logHRi)/∑∆SBPi2*Wi]
where ∆SBPi is the mean difference in systolic blood pressure
over time between randomised treatment groups and logHRi
andWi are natural log transformed hazard ratios of randomised
treatment on each outcome and its inverse variance in trial i.48 49
For the head to head comparisons, where much smaller
differences in blood pressure were observed, we calculated
similar blood pressure weighted estimates per 1 mm Hg
difference between the randomised groups.
Continuous effects of eGFR
We tested for interactions between eGFR fitted as a continuous
variable and the effects of treatment on the risk of cardiovascular
outcomes to maximise statistical power to detect possible
differences in the effects of the various regimens according to
baseline eGFR. Interactions between blood pressure lowering
treatment and eGFR taken as a continuous variable were
investigated with Cox proportional hazard regression models
or logistic regression models including study treatment,
continuous eGFR values, and their interaction term. The
regression coefficient for the latter term estimates the log ratio
of hazard ratios for comparing treatments, which shows the
effect of a unit increase in eGFR on the treatment effect. Twenty
three trials contributing individual participant data were included
in these analyses. The log ratios of hazard ratio were pooled
with a random effects model. The pooled summary was
exponentiated to arrive at the overall estimated ratio of hazard
ratio for a 10 mL/min/1.73 m2 decrement in eGFR for each
outcome.
Meta-regression analysis according to kidney
function
Meta-regression analyses were conducted to explore the
association between the difference in systolic blood pressure at
follow-up between randomised groups and the risk estimate for
cardiovascular events in different subgroups, where the response
variable was the natural log transformed hazard ratio and the
explanatory variable was the effect of treatment on blood
pressure. This was investigated across trials by using random
effects meta-regressionmodels with inverse variance weighting.
Analyses were carried out with the “metareg” routine in Stata.
We fitted separate regression lines for each subgroup and
compared the slopes of these lines to test for a differential effect
of systolic blood pressure reduction on risk reduction between
subgroups for each outcome by adding an interaction term
between subgroup and systolic blood pressure reduction during
follow-up to the model.
As trial participants could contribute only once to a given
meta-analysis with regard to the comparison of active treatment
versus placebo and a given meta-regression analysis, trials with
randomisation to three treatment arms21 35 38 contributed results
from only two of the possible three treatment comparisons, with
the control arm participants divided randomly between the two
comparisons. For similar reasons, for factorial trials that included
randomisation to different intensities of blood pressure lowering
and randomisation to different drug treatments,31 32 34 45 we
included only the results of the randomisation to different
intensities of blood pressure lowering.
All statistical analyses were conducted with SAS software for
Windows, version 9.1 (SAS Institute, Cary, NC) or Stata, release
9.2 (StataCorp, College Station, TX). In every analysis a P<0.05
was taken to indicate that a result was possibly not due to
chance, although each case required careful interpretation, given
the large numbers of comparisons made.
Results
Characteristics of trials, patients included and
follow-up blood pressure levels
Twenty five trials,14 15 21-44 including 152 290 individuals,
provided data for these analyses (tables 1, 2, and 3⇓⇓⇓). The
trials involved had a low risk of bias (appendix table 1).
There were 121 995 individuals (80%) with eGFR ≥60
mL/min/1.73 m2 (mean eGFR 81 (SD 17) mL/min/1.73 m2) and
30 295 individuals (20%) with eGFR <60 mL/min/1.73 m2
(mean 52 (SD 7) mL/min/1.73 m2) at baseline (table 4⇓). Only
439 individuals (0.3%) had eGFR <30 mL/min/1.73 m2 at
baseline. Individuals with reduced eGFR tended to be older (68
v 63) and were more likely to be women (60% v 40%) (table
4). Data on urinary protein excretion were available for 37 161
individuals, mostly from trials that compared ACE inhibitor
based regimens with placebo. Proteinuria was present in 2500
(7%) of these individuals, and patients with proteinuria were
more likely to be men (66% v 55%) and tended to have a higher
serum creatinine concentration at baseline (91 μmol/L v 86
μmol/L). The baseline characteristics of each trial included were
well balanced between the randomised treatment allocations
(appendix table 2). There was some evidence of publication
bias (Egger’s test P=0.05) across the studies (appendix fig 4).
A trim and fill analysis,47 however, did not change the pooled
estimate.
Effects of active treatment compared with
placebo in patients with different baseline
eGFR
For major cardiovascular events, allocation to an ACE inhibitor
based regimen reduced the risk of a major cardiovascular event
by about a sixth (hazard ratio 0.81, 95% confidence interval
0.73 to 0.90). This reduction seemed similar irrespective of
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baseline eGFR (0.81 (0.72 to 0.91) for eGFR of ≥60
mL/min/1.73m2 v 0.81 (0.73 to 0.89) for eGFR of <60
mL/min/1.73m2; P=0.99 for homogeneity; fig 1⇓). There was
significant heterogeneity in treatment effect between trials for
the subgroup with eGFR >60 mL/min/1.73 m2 (Q=19.4, df=8,
P=0.01, I2=59%) but not in the subgroup with reduced GFR (see
appendix fig 2). Sensitivity analyses that excluded the three
trials15 22 23 in which the hazard ratios were unavailable for the
risk estimates did not make any material difference to the
findings (hazard ratio 0.80 (0.68 to 0.92) for eGFR ≥60 and
0.76 (0.68 to 0.85) for eGFR<60).
Calcium antagonist based regimens likewise reduced the risk
of major cardiovascular events by about a third, once again with
similar effects among individuals with and without reduced
eGFR (fig 1⇓). Similar findings were observed for secondary
outcomes (appendix table 3).
Blood pressure weighted meta-analysis of
effect of active treatment in patients with
different baseline eGFR
To account for different magnitudes of reduction in blood
pressure with different drug classes, we also performed a
meta-analysis weighted for blood pressure reduction (fig 2⇓).
A 5 mm Hg reduction in systolic blood pressure had almost
identical effects on major cardiovascular events at different
eGFR, with no difference between ACE inhibitor and calcium
channel blocker based regimens compared with placebo (fig
2⇓). As the results for each class of drugs were similar, we
undertook a pooled analysis, which showed that these regimens
reduced the risk of major cardiovascular events by 17% per 5
mmHg reduction in systolic blood pressure in both those below
and above eGFR of 60 mL/min/1.73m2 (hazard ratio 0.83 (95%
confidence interval 0.76 to 0.90) and 0.83 (0.79 to 0.88),
respectively). The proportional reductions in major
cardiovascular events were also similar when participants were
divided into three eGFR categories (≥60, 45-59, and <45
mL/min/1.73 m2).
Net absolute effects of treatment in patients
with different baseline eGFR
We investigated the absolute effects of active treatment in
patients with eGFR above and below 60 mL/min/1.73m2 on the
basis of the incidence rates for major cardiovascular events in
the placebo groups and the blood pressure weighted hazard
ratios of active treatment. Overall, 21 major cardiovascular
events were prevented for every 1000 participants treated (ACE
inhibitor or calcium channel blocker based regimens) compared
with placebo (number needed to treat (NNT) for preventing one
event over an average of four years was 47). Although the
magnitude of the relative effects of active treatment were similar
across eGFR, the absolute benefit for major cardiovascular
events was 50% higher at lower eGFR, with 28 events prevented
for every 1000 patients with eGFR below 60 mL/min/1.73m2
(NNT=35) compared with 19 for patients with eGFR above 60
mL/min/1.73m2 (NNT=53).
Effects of more intensive compared with less
intensive blood pressure lowering regimens
in patients with different baseline eGFR
As shown in figure 3⇓, for the trials targeting different blood
pressure goals there were wide confidence intervals but no
evidence of heterogeneity of treatment effects on major
cardiovascular events according to baseline eGFR (hazard ratio
0.87 (95% confidence interval 0.73 to 1.03) for eGFR of ≥60
mL/min/1.73m2 v 1.24 (0.62 to 2.48) for eGFR of <60
mL/min/1.73m2; P=0.33 for homogeneity). The effects of more
intensive compared with less intensive regimens for secondary
outcomes are shown in appendix table 4. A sensitivity analysis
that included one further trial45 that comprised only patients
with reduced eGFR made little difference to the findings (1.10
(0.76 to 1.60) in patients with eGFR <60 mL/min/1.73m2;
P=0.24 for heterogeneity).
Effects of different drug classes in patients
with different baseline eGFR
In the trials comparing blood pressure lowering regimens based
on different drug classes, there were no clear differential effects
on major cardiovascular events (fig 4⇓) between groups with
different eGFR for any comparison (all P>0.6 for homogeneity).
The results of the comparisons between calcium antagonist
based regimens and conventional treatment after exclusion of
one trial43 in which the hazard ratios were unavailable for the
risk estimates (hazard ratio 1.04 (95% confidence interval 0.98
to 1.11) for eGFR ≥60 and 1.05 (0.95 to 1.16) eGFR <60) and
the results of the comparisons among different drug classes in
participants with eGFR <60 after inclusion of one trial45 that
contributed patients only to the reduced eGFR stratum (1.00
(0.91 to 1.10) for ACE inhibitor v conventional; 1.03 (0.93 to
1.14) for calcium antagonist v conventional; 0.96 (0.86 to 1.08)
for ACE inhibitor v calcium antagonist) remained substantially
unchanged. The findings were also similar in the blood pressure
weighted comparisons (appendix fig 3). For the secondary
outcomes, there was heterogeneity in the effect of ACE inhibitor
based regimens against heart failure compared with calcium
antagonist based regimen by eGFR, with evidence of greater
benefit for ACE inhibitors among participants with eGFR >60
(appendix table 5).
Interactions between blood pressure lowering
treatment and continuous eGFR.
We found no evidence of a significant interaction between
baseline eGFR and treatment effect for major cardiovascular
events (all P>0.18, fig 5⇓). For the secondary outcomes, we
observed just two significant interactions between eGFR and
treatment among 30 comparisons, suggesting they might have
arisen by chance (appendix fig 4).
Association between trial differences in blood
pressure and proportional risk reductions
The association between blood pressure lowering achieved and
the proportional reduction in risk of cardiovascular events
achieved was similar in participants with reduced compared
with normal eGFR when assessed with meta-regression. A 5
mm Hg reduction in systolic blood pressure during follow-up
was associated with a relative risk reduction of 14.2% (95%
confidence interval 8.6% to 19.5%) in participants with normal
eGFR and 12.1% (2.9% to 20.4%) for participants with reduced
eGFR for the primary outcome of major cardiovascular events
(P=0.69 for homogeneity) (fig 6⇓).
Effects of active treatment compared with
placebo in patients with and without
proteinuria at baseline
There was no evidence of heterogeneity (P=0.84 for
homogeneity) in the effect of ACE inhibitor based regimens on
major cardiovascular events between individuals with (hazard
ratio 0.94, 95% confidence interval 0.84 to 1.05) and without
proteinuria (0.90, 0.63 to 1.29) per 5 mm Hg reduction in
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systolic blood pressure, although only limited data were
available (fig 7⇓). There were not enough trials with data on
proteinuria to allow reliable assessment of the comparative
effects of calcium antagonists, different blood pressure targets,
and different drug classes in patients with and without
proteinuria.
Discussion
Principal findings
These analyses, based on a large volume of data with several
trials that included people who did not have hypertension,
provide compelling evidence for the cardiovascular benefits of
reduction in blood pressure in people with stage 1-3 chronic
kidney disease. While the proportional reductions in the risk of
major cardiovascular events were similar in people with and
without evidence of chronic kidney disease, individuals with
chronic kidney disease stood to gain much larger absolute
benefits because their baseline risk was much higher. The high
prevalence of chronic kidney disease in the community (10-15%)
means that strategies to increase the use of blood pressure
lowering treatments among this group are likely to be highly
effective at reducing the burden of cardiovascular mortality and
morbidity.5 6 14 16
Effect of different drug classes on
cardiovascular events in people with chronic
kidney disease
The data provided no clear evidence that any particular drug
class provided greater or lesser cardiovascular protection for
patients with compared with those without chronic kidney
disease. This was true both for subgroup analyses done by
dichotomising patients according to usual eGFR cutpoints and
for the more powerful analyses done with eGFR fitted as a
continuous variable. Intriguingly, the cardiovascular benefits
of ACE-I and calcium channel blockers compared with placebo
were virtually identical once we accounted for the small
differences in blood pressure lowering achieved in analyses
weighted for blood pressure reduction, although different types
of calcium channel blockers were used in these analysis,
including dihydropyridines (such as amlodipine and nisoldipine)
and phenylalkylamines (such as verapamil). Similar findings
were observed in the meta-regression analyses and in head to
head comparisons that also included diuretics or β blockers.
These results suggest that the cardiovascular benefits of lowering
blood pressure in people with chronic kidney disease are more
dependent on the blood pressure lowering effect achieved than
on the agent selected. This is an observation broadly consistent
with the previously reported findings across the trial
populations,9 although small benefits independent of blood
pressure reduction have been reported for ACE inhibitors and
coronary heart disease.50 Additionally, a recent randomised
control trial in patients with hypertension showed that treatment
with benazepril plus amlodipine was superior to that with
benazepril plus hydrochlorothiazide in preventing cardiovascular
events, despite no clear difference in the achieved blood pressure
during follow-up.51 Several studies have also suggested that
drugs acting via the renin-angiotensin system provide greater
protection against renal outcomes, but we did not assess these
outcomes.13 It is therefore possible there might be additional
benefits (or harms) independent of blood pressure associated
with individual classes of drugs, but this analysis highlights the
key role of blood pressure lowering as a driver of reduction in
cardiovascular risk. Future analyses including data from
completed and ongoing trials should clarify whether greater
effects on renal outcomes achieved by these drug classes in
patients with proteinuria will translate into greater protection
against major vascular events
Effects of intensive blood pressure lowering
on cardiovascular events in chronic kidney
disease
There was no clear benefit for more intensive compared with
less intensive blood pressure lowering regimens in people with
chronic kidney disease, although there was only limited power
for these analyses and little capacity to detect whether the effects
of treatment varied according to kidney function; lower blood
pressure targets have, nonetheless, been suggested to improve
renal outcomes in people with proteinuric chronic kidney
disease,52 53 providing some support for the earlier
recommendation that blood pressure be lowered more
intensively in these high risk patients. The effects of more
intensive blood pressure lowering on cardiovascular outcomes
in people with kidney disease remains to be demonstrated by
future trials, such as the ongoing Systolic Blood Pressure
Intervention Trial (SPRINT, NCT01206062).
Strengths and weaknesses
These analyses, based on more than 150 000 trial participants
and 15 000 major cardiovascular events, are uniquely powerful
and provide precise estimates of the effects on major
cardiovascular events of the most widely used regimens to lower
blood pressure in patients with and without chronic kidney
disease. There are, however, several important limitations.
Firstly, most participants with chronic kidney disease in this
study were in stage 3a (mostly in the range of 45-60
mL/min/m2), and few participants (0.4%) had eGFR ≤30
mL/min/1.73 m2. As a result, the applicability of these results
to populations with stage 4-5 disease is uncertain, although they
are broadly consistent with a meta-analysis of blood pressure
lowering in patients with severe kidney disease who were
receiving dialysis.54 Likewise, few participants had documented
proteinuria and only limited numbers of events were available
in this population group. Secondly, the analyses depend on the
trial data that were available at the start of this study and we
could not investigate some questions of interest. These include
the effects on cardiovascular outcomes of regimens based on
angiotensin receptor blockers and the separate evaluation of
regimens based on β blockers or diuretics alone.When possible,
we contacted investigators directly to request missing data or
extracted data from published reports to complement available
data. Therefore, while we acknowledge this is not a complete
dataset, we believe selection bias in this study is minimised by
the strict pre-specification of trial eligibility criteria including
those related to trial size, quality, randomisation process,
outcome definition, treatment comparison, and analysis as
specified the published study protocol.20 Furthermore, and in
line with recommendations for reporting individual patient data
meta-analyses where there are missing data,55 we formally
assessed publication bias in this study.We found some evidence
of publication bias, which is likely to overestimate the pooled
treatment effects, although a trim and fill analysis did not change
the pooled estimate. Thirdly, we collected data based on the
MDRD-GFR equation from the collaborators as the CKD-EPI
equation had not yet been reported when the collaboration was
first established. Indeed, it has been suggested that the CKD-EPI
equation might be superior to the MDRD-GFR equation for
estimating GFR in people with eGFR of ≥60 mL/min/1.73 m2,
but both equations have similar accuracy in people with eGFR
of <60 mL/min/1.73 m2.56 As we divided into only two
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categories, below and above 60 mL/min/1.73 m2, rather than
the detailed categories of eGFR, we believe this issue would be
unlikely to have an important impact on the findings. Finally,
uncertainty in estimation of the reduction in blood pressure in
each trial will reduce the accuracy of estimation of the treatment
effect of blood pressure lowering on cardiovascular risk.
Conclusions
These overviews provide clear evidence that a broad range of
different blood pressure lowering regimens provide protection
against cardiovascular complications in patients with and
without chronic kidney disease. Specifically, blood pressure
lowering per se, not the effects of a particular drug class (such
as renin-angiotensin system blockade), seems to be significantly
associated with lower cardiovascular risk in early stage chronic
kidney disease, possibly suggesting the importance of blood
pressure lowering as a driver of cardiovascular risk reduction.
These findings should help to guide decision making for many
physicians and their patients, given the absence of clear evidence
to date supporting recommendations (for particular drug classes)
to reduce the cardiovascular risk among people with early stage
chronic kidney disease. As people with chronic kidney disease
are at greatly increased cardiovascular risk, the benefits of blood
pressure lowering in this population are large. The broader use
of blood pressure lowering drugs, along with other proved
treatments such as lipid lowering,57will both improve outcomes
for affected individuals and help to reduce the escalating global
burden of cardiovascular disease.
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Tables
Table 1| Characteristics of included double blind trials comparing active treatment for blood pressure control and placebo in patients with
chronic kidney disease
No (%) with
proteinuria
No (%) with
eGFR <60
Mean (SD) eGFR
(mL/min/1.73m2)
Follow-up
(years)
Kidney function
exclusion criteriaEntry criteriaNo*
Treatment
comparisonTrial
ACE inhibitor v placebo
0 (0)†37 (6)81 (15)3.6sCr >133 μmol/LHBP+DM604Trandolapril v placeboBENEDICT21
1286 (26)‡999 (20)77 (21)3.9sCr >150 μmol/LDM+nephropathy4912Ramipril v placeboDIAB-HYCAR22
NA1999 (17)75 (18)4.2sCr >150 μmol/LCHD12 218Perindopril v placeboEUROPA23
NA3394 (37)§NA4.5NoneCHD, CVD, or
DM + RF
9297Ramipril v placeboHOPE14
31 (5)¶119 (19)73 (16)4.7NoneCHD or CVD617Ramipril v placeboPART224
NA1172 (19)78 (24)3.9NoneCerebrovascular
disease
6105Perindopril
(+/−indapamide) v
placebo(s)
PROGRESS25
NA115 (26)68 (13)4NoneCHD460Enalapril v placeboSCAT26
7 (0.8)†70 (8)76 (12)3.8Creatinine
clearance <60% of
normal age adjusted
value
Microalbuminuria864Fosinopril v placeboPREVEND-IT27
406 (4)**2139 (19)78 (25)4.3NoneDM11 140Perindopril
(+indapamide) v
placebos
ADVANCE28
NA1355 (16)78 (19)4.8sCr >177 μmol/LCHD8290Trandolapril v placeboPEACE15
Calcium antagonist v placebo
0 (0)†43 (7)81 (15)3.6sCr >133 μmol/LHBP+DM
+nephropathy
605Verapamil v placeboBENEDICT21
72 (9)249 (30)67 (13)3NoneCHD825Amlodipine v placeboPREVENT29
109 (2)¶1,563 (33)69 (18)2.6sCr >180 μmol/LHBP ≥60 years4695Nitrendipine v placeboSYST-EUR30
ACE=angiotensin converting enzyme; CHD=coronary heart disease; CVD=cardiovascular disease; DM=diabetes mellitus; HBP=high blood pressure; sCr=serum
creatinine.
*No of all randomised participants.
†Proteinuria defined as urinary albumin excretion ≥200 μg/min or ≥300 mg/day.
‡Proteinuria defined as urinary albumin concentration ≥200 mg/L.
§Mean eGFR and % of eGFR < 65 mL/min, estimated by Cockcroft-Gault formula (HOPE).
¶Proteinuria defined as dipstick test 1+ or more.
**Proteinuria defined as urinary albumin creatinine ratio ≥300 μg/mg.
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Table 2| Characteristics of included trials comparing more intensive and less intensive regimens to treat raised blood pressure in patients
with chronic kidney disease
No (%) with
proteinuria
No (%) with
eGFR <60
Mean (SD) eGFR
(mL/min/1.73m2)
Follow-up
(years)
Kidney function
exclusion
criteriaEntry criteria
Trial
designNo*
Treatment
comparisonTrial
89 (19)†120 (26)70 (16)5.3sCr >265 μmol/LHBP+DMOpen470DBP ≤75 mm Hg v
≤90 mm Hg
ABCD (H)31
51 (11)†137 (29)70 (17)5.3sCr >265 μmol/LDMOpen480DBP 10 mm Hg
below baseline v
80-89 mm Hg
ABCD (N)32
NA3619 (19)75 (19)3.8NoneHBPOpen‡18 790DBP ≤80 mm Hg v
≤85 or ≤90 mm Hg
HOT33
NA103 (9)82 (19)8.4sCr >175 μmol/LHBP+DMOpen1148DBP < 85 mm Hg v
<105 mm Hg
UKPDS-HDS34
NA1094 (100)§46 (13)§4.1GFR<20
mL/min/1.73m2
HBP+nephropathy,
Afr
Open1094MAP ≤92 mm Hg v
102-107 mm Hg
AASK45
Afr=African American; CVD=cardiovascular disease; DB=double blind; DBP=diastolic blood pressure; DM=diabetes mellitus; HBP=high blood pressure; MAP=mean
arterial pressure; sCr=serum creatinine.
*No of all randomised participants.
†Proteinuria defined as urinary albumin excretion >200 μg/min or >300 mg/day.
‡PROBE (Prospective, Randomized, Open with Blinded Endpoint evaluation) design trials.
§Mean eGFR and % of eGFR <65 mL/min, estimated by 125-iothalamate clearance (AASK).
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Table 3| Characteristics of included trials comparing regimens based on different drugs to treat raised blood pressure in patients with
chronic kidney disease
No (%) with
proteinuria
No (%) with
eGFR <60
Mean (SD) eGFR
(mL/min/1.73m2)
Follow-up
(years)
Kidney function
exclusion
criteriaEntry criteria
Trial
designNo*
Treatment
comparisonTrial
ACE inhibitor v diuretic or β blocker
NA4163 (18)78 (20)4.9sCr >177 μmol/LHBP+RFDB24 309Lisinopril v
chlorthalidone
ALLHAT35
NA1860 (31)68 (15)4.1sCr >221 μmol/LHBP, age 65-84Open†6083Enalapril v
hydrochlorothiazide
ANBP236
438 (4)‡1069 (10)78 (15)6.1sCr >150 μmol/LHBPOpen†10 985Captopril v β blocker or
diuretic
CAPPP37
NA1526 (35)66 (15)5NoneHBP, age 70-84Open†4418Enalapril or lisinopril v
atenolol or metoprolol
or pindolol or
hydrochlorothiazide +
amiloride
STOP-238
NA68 (9)83 (19)8.4sCr >175 μmol/LHBP+DMDB758Captopril v atenololUKPDS-HDS39
NA877 (100)¶46 (13)¶4.1GFR <20
mL/min/1.73m2
HBP+nephropathy,
Afr
DB877Ramipril v metoprololAASK§45
Calcium antagonist v diuretic or β blocker
NA4149 (18)78 (20)4.9sCr >177 μmol/LHBP+ RFDB24 303Amlodipine v
chlorthalidone
ALLHT35
11 (0.5)††215 (9)80 (18)4NoneHBPDB2334Lacidipine v atenololELSA40
NA42 (10)90 (27)5NoneHBP, age ≥60DB429Nicardipine v
trichlormethiazide
NICS-EH41
NA1664 (15)74 (15)5NoneHBPOpen†10 881Diltiazem v β blocker or
diuretic
NORDIL42
NA1467 (33)66 (15)5NoneHBP, age 70-84Open†4409Felodipine or isradipine
v atenolol or metoprolol
or pindolol or
hydrochlorothiazide +
amiloride
STOP-238
NA134 (10)82 (24)2sCr >150 μmol/LHBPDB/Open1414Verapamil v
chlorthalidone
VHAS43
NA658 (100)¶46 (13)¶4.1GFR <20
mL/min/1.73m2
HBP+nephropathy,
Afr
DB658amlodipine v
metoprolol
AASK§45
ACE inhibitor v calcium antagonist
89 (19)**120 (26)70 (16)5.3sCr >265 μmol/LHBP+DMDB470Enalapril v nisoldipineABCD (H)31
51 (11)**137 (29)70 (17)5.3sCr >265 μmol/LDMDB480Enalapril v nisoldipineABCD (N)32
NA3056 (18)78 (20)4.9sCr >177 μmol/LHBP+CVD RFDB18 102Lisinopril v amlodipineALLHAT35
0 (0)**36 (6)81 (15)3.6sCr >133 μmol/LHBP+DMDB605Trandolapril v
verapamil
BENEDICT21
NA166 (12)89 (27)3sCr >177 μmol/LHBP+CHDOpen†1650ACE inhibitor v
nifedipine
JMIC-B44
NA1507 (34)66 (15)5NoneHBP, age 70-84Open†4401Enalapril or lisinopril v
felodipine or isradipine
STOP-238
NA653 (100)¶46 (13)¶4.1GFR <20
mL/min/1.73m2
HBP+nephropathy,
Afr
DB653Ramipril v amlodipineAASK§45
ACE=angiotensin converting enzyme; Afr=African American; CHD=coronary heart disease; CVD=cardiovascular disease; DB=double blind; DM=diabetes mellitus;
HBP=high blood pressure; sCr=serum creatinine.
*No of all randomised participants.
†PROBE (Prospective, Randomized, Open with Blinded Endpoint evaluation) design trials.
‡Proteinuria defined as dipstick test 1+ or more.
§AASK trial included for sensitivity analysis, because patients contributed only to reduced eGFR stratum.
¶Mean eGFR and % of eGFR <65 mL/min, estimated by 125-iothalamate clearance (AASK).
**Proteinuria defined as urinary albumin excretion ≥200 μg/min or ≥300 mg/day.
††Proteinuria was defined as urinary albumin excretion more than 500 mg/L.
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Table 4| Mean baseline characteristics and follow-up differences in blood pressure between randomised groups according to different
baseline glomerular filtration rate (eGFR)
Systolic/diastolic(mm Hg)Baseline eGFR
(mL/min/1.73m2)
Baseline Cr
(mmol/L)Men (%)Age (years)No (%)*
Treatment
comparison During follow-upBaseline
All trials†
141/81156/9181836063121 995 (80)eGFR ≥60
144/80160/9052115406830 295 (20)eGFR <60
Active treatment v placebo†
ACEI v placebo:
135/78141/828284756242 896 (79)eGFR ≥60
137/77145/8252117556711 399 (21)eGFR <60
Calcium antagonist v placebo:
151/81164/85778249664252 (70)eGFR ≥60
154/80169/845210624701855 (30)eGFR <60
More intensive v less intensive regimens
142/83168/1048183586016 687 (81)eGFR ≥60
143/83170/1045211435653979 (19)eGFR <60
Comparisons of drugs classes
ACEI v diuretic or β blocker:
143/83156/908183546336 540 (81)eGFR ≥60
146/81162/895111638718686 (19)eGFR <60
Calcium antagonist v diuretic or β blocker:
144/83159/938182536434 838 (82)eGFR ≥60
147/82163/915211637707671 (18)eGFR <60
ACEI v calcium antagonist:
141/80153/878382546719 520 (80)eGFR ≥60
147/80161/885111941725022 (20)eGFR <60
ACEI=angiotensin converting enzyme inhibitor.
*No of participants with available data on GFR.
†Data for age, sex, baseline SBP, baseline serum creatinine, and baseline eGFR unavailable, and same degree of blood pressure reductions during follow-up in
each kidney function group were assumed in HOPE and PEACE.
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Figures
Fig 1 Effects of angiotensin converting enzyme inhibitor or calcium antagonist based regimens v placebo for risk of major
cardiovascular events according to kidney function status. P value for homogeneity indicates consistency of effect of
treatment regimen among subgroup. Overall mean difference in systolic and diastolic blood pressure during follow-up in
actively treated/first listed regimens v control/second listed regimens, calculated by weighting difference observed in each
contributing trial by number of patients in trial. Negative values indicate lower mean systolic and diastolic blood pressure
during follow-up in actively treated/first listed groups than in control/second listed groups
Fig 2 Effects of angiotensin converting enzyme inhibitor or calcium antagonist based regimens v placebo per 5 mm Hg
reduction in systolic blood pressure over time on risk of major cardiovascular events according to kidney function status.
Pooled estimates estimated with relative risk model weighted for blood pressure reduction. Values show relative risk per 5
mm Hg reduction in systolic blood pressure over time. *Data from HOPE trial not available for analysis of three GFR
categories
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Fig 3 Effects of more intensive v less intensive blood pressure lowering regimens for risk of major cardiovascular events
according to kidney function status
Fig 4 Effects of blood pressure lowering regimens based on different drug classes for risk of major cardiovascular events
according to kidney function status
Fig 5 Proportional increase in risk ratio of treatment effect on major cardiovascular events for every 10 mL/min/1.73 m2
decrement in eGFR
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Fig 6 Associations between systolic blood pressure reduction and risk reduction for major vascular events according to
kidney function status. Centre of each circle is placed at estimates of risk ratio for each trial. Area of each circle is proportional
to variance of log odds ratio. Fitted lines represent summary meta-regressions for total major cardiovascular events.
Intercepts were 0.96 (0.93 to 1.01) for eGFR ≥60 mL/min/1.73 m2 and 0.97 (0.89 to 1.04) for eGFR <60 mL/min/1.73 m2
Fig 7 Effects of angiotensin converting enzyme inhibitor or calcium antagonist based regimens v placebo per 5 mm Hg
reduction in systolic blood pressure over time on risk of major cardiovascular events according to proteinuria status
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